Under UK law, inventions are protected through patents. There is no protection granted by way of design patents, and registered design rights must not be used to protect a feature that is purely technical in nature.
The legal protection from patents is primarily governed by statute (the Patents Act 1977), but the statute is interpreted by judges such that the case law will inform the likelihood of an invention being afforded protection.
To obtain a patent in the UK, an applicant may complete the relevant paperwork and formalities (including filing the claims, description and full text of the patent) and apply directly to the UK Intellectual Property Office (the “UK IPO”). As the UK is a member of the European Patent Convention (EPC), a prospective patent holder may also apply to the European Patent Office (EPO) for the grant of a European Patent designating the UK amongst the states in which the European Patent should be granted. Later, once that European Patent has been granted, the patentee should apply to the UK IPO and complete the formal registration step. Patentees should note that applications filed with the EPO in English must also be translated into French and German.
It is also possible to first file an international patent application (PCT) via the UK IPO, which will be provided to the World Intellectual Property Organisation (WIPO) for processing. The EPO is involved in granting a PCT, acting in the capacity of an International Search Authority. Following publication of the application, the prospective patentee must then apply in the jurisdictions in which it would like the patent to be considered for grant and ultimately effective.
The timeline to grant varies. Patents filed with the EPO typically take four years or more to be granted. Applicants may request an accelerated examination in the EPO, which is subject to the EPO's discretion and may only be accepted where practically feasible. Patents filed with the UK IPO can take between two-and-a-half and four-and-a-half years to be granted, although the time to grant can be significantly less. Any third-party observations made during the course of the grant procedure will inevitably delay the grant as the Patent Office will consider these objections.
In most cases, representation is not required, but given the specialised nature of drafting a patent application, patent agents are used in most instances. If the applicant has neither residence nor their principal place of business in an EPO contracting state, the applicant must appoint a representative.
The costs associated with granting intellectual property rights vary depending on the type of rights and any representation retained. A rough estimate for filing a patent application ranges from GBP4,000 to GBP7,500. Additionally, the costs for filing a patent with the UK Intellectual Property Office (UK IPO) are approximately GBP300 to GBP350, depending on the number of claims and the patent length.
The term of a patent is 20 years from the filing date. The term can be extended for up to five additional years by Supplementary Protection Certificates (SPCs) (see 1.6 Further Protection After Lapse of the Maximum Term).
In order to enjoy the full 20 years of protection, the owner must pay a renewal fee annually from the fourth anniversary of the filing date onwards (at the UK IPO) or the third anniversary onwards at the EPO.
Subject to a patent being found valid and infringed, the owner will be entitled to the following remedies (as set out in more detail in 6.1 Remedies for the Patentee):
Registered rights may be identified via the relevant registers – for example, UK patent rights can be found via Ipsum and European patents via the EPO or Espacenet. There is no register listing patents applicable to certain products or processes.
In addition to the standard 20-year patent term, certain medicinal products may qualify for SPC, which can extend the protection period by an additional five years. The duration of the SPC is calculated by taking the time elapsed between the date the application for the basic patent was submitted and the date of the first marketing authorisation (MA) and then subtracting five years from that total.
SPCs were first introduced through EU regulations and subsequently imported directly into UK law following Brexit (Section 128B and Schedule 4A, Patents Act). Products protected by SPCs must first be protected by a patent in force and be subject to an active Marketing Authorisation.
Additionally, where studies have been conducted into the effects of the medicinal product on children, the patentee can apply for a further six-month paediatric extension to the duration of the SPC.
During the procedure of registering a UK patent, third parties may intervene by filing oppositions or observations. During the examination of a patent, third parties may file observations with the patent office (UK IPO, EPO or WIPO as applicable) or UK IPO, respectively. Following the grant, filing oppositions within a certain timeframe is possible. The objections should be filed within nine months of the grant at the EPO.
It is not possible to file an opposition to a patent registered with the UK IPO, but an opinion may be requested. The UK IPO’s senior examiners will review the patent and publish a non-binding opinion typically within three months. Following the publication of an opinion that considers the patent invalid, the UK IPO may also decide to revoke the patent.
During the examination of a UK patent, the IPO issues opinions regarding the registrability of the patent. Applicants are given the opportunity to correct any deficiencies identified. If an application is still refused after this process, the applicant can appeal the initial decision directly to the UK IPO. Additionally, applicants have the right to appeal to the High Court, notably demonstrated in the recent case of Thaler v Comptroller of Patents, where the case was ultimately taken to the Supreme Court.
In the case of patents filed with the EPO, decisions of the Examination Division can be appealed to the Technical Board of Appeal.
There is a six-month grace period at the UK IPO during which late payment of the annual renewal fee may be made (additional late payment fees also apply). After this period, the patent right lapses. However, if the patentee has a good reason as to why the deadline was missed, the patentee may apply to restore the patent within 13 months of the expiry of the grace period.
A UK patent may be amended post-grant in certain restricted aspects (the most important consideration in a post-grant amendment context will typically be whether the amendment adds matter over and above the patent application as filed). The patent may not be amended to extend the scope of its protection. The patentee may apply to the IPO or court to request an amendment (in the case of the latter, the IPO should also be informed and sent the application). Patentees should note that applications to amend will be published, and third parties may oppose prior to the relevant authority issuing its decision.
A claim may be brought by the owner (or an exclusive licensee) of a patent in the first-instance courts (see 2.3 Courts With Jurisdiction). Alternative dispute resolution is encouraged by the courts but is not mandatory. Most large-scale patent cases proceed to be heard before the court through to final judgment.
Opposition proceedings cannot be brought in the UK; however, it is common to file nullity proceedings in the UK while parallel EPO opposition proceedings are ongoing. Post-grant review is not available.
Any party can initiate an action to revoke a patent without needing to establish standing. Revocation actions can be brought before the courts of England and Wales or the UK IPO. Additionally, infringement and validity opinions can be requested from the UK IPO, although these opinions are non-binding. Nevertheless, a patent may be revoked if it is determined to be invalid by the UK IPO.
A declaration of non-infringement may be granted by the Patents Court and the Intellectual Property Enterprise Court (IPEC) in main proceedings or upon application to the Comptroller. “Arrow” declarations (ie, declarations that a claimant’s process or product was obvious or not novel) can be sought by a third party to guard against future infringement proceedings for patents granted at a later date. Arrow declarations are available in England and Wales and can be granted where “they will serve a useful purpose”.
The Patents Court, a division of the High Court of England and Wales, hears most patent cases, while less complex patent cases may be heard in the IPEC. Appeals from the Patents Court are made to the Court of Appeal, and further appeals are made to the Supreme Court.
In addition to the courts, a revocation action may be brought before the UK IPO.
A main action for patent infringement can be filed at any time once a national UK patent has been granted (and in certain circumstances before a patent has been granted if examination at the EPO has concluded but a formal grant has not yet taken place). Formal demand or warning letters are not a prerequisite for filing a claim, nor is engaging in mediation.
Although parties are not required to be represented by a lawyer, it is uncommon that they not be. In UK patent litigation, it is most common for a party to be represented by a firm of solicitors and independent barristers.
Preliminary injunctions (PIs) are available in the UK as an interim equitable remedy. The court grants them when there is a serious issue to be tried and when the balance of convenience favours granting the PI. Applications for PIs can be made on an ex parte basis if appropriate, but it is more common for such applications to be issued inter partes within the context of ongoing main proceedings. In PI proceedings, patent validity is not presumed; the alleged infringer has the opportunity to present evidence to contest it during the PI proceedings.
The timing and length of PI proceedings depend largely on facts and are based on commercial urgency. As a discretionary equitable remedy, courts expect that a party seeking a PI will do so expeditiously – the failure of an applicant to act with sufficient urgency in all circumstances is likely to count as a factor against the grant of the PI sought. The court will consider the factors from American Cyanamid.
When obtaining a PI, the claimant must provide a cross-undertaking to compensate the alleged infringer for damages in the event the injunction was found to have been unjustified. The undertaking remains in place until a final order is made following the first-instance action and any appeal.
In pharmaceutical or medical device patent cases, if an interim injunction affects dealings with the National Health Service (NHS), the patentee may be required to provide cross-undertakings in damages in favour of the NHS, and they would also be entitled to damages if the patentee is unsuccessful.
Protective letters are not available in England and Wales.
The limitation period for bringing a claim for patent infringement is six years from the date the cause of action accrued (under Section 2, Limitation Act 1980).
Pre-action disclosure is not available as of right. Orders for pre-action disclosure can be sought if the would-be claimant can demonstrate that this may settle the dispute without the need for proceedings. The court can also order a third party to disclose documents to an applicant before proceedings have started in order to enable the applicant to commence proceedings against the appropriate party.
Disclosure in the main proceedings in patent cases is most common in relation to the issue of infringement rather than validity. Disclosure by an alleged infringer on the issue of infringement is commonly provided by way of a Product and Process Description (PPD), which is a self-contained document provided in lieu of the relevant underlying documents and sets out sufficient information for the court to determine whether or not the patent has been infringed.
Disclosure in the main proceedings follows the provision of an “Initial Disclosure List”, which is provided by the parties when they provide their initial pleadings and sets out the documents upon which they rely. Significantly, there is no requirement to disclose documents that adversely affect a party’s case as part of the Initial Disclosure List.
Unless ordered otherwise, the use of documents obtained in disclosure is restricted to English proceedings and cannot be used in other jurisdictions.
Search and seizure orders are available as a form of interim mandatory injunction, and applications are made ex parte, but these are not a regular feature of patent litigation in England and Wales.
To start an action, a claimant must prepare a claim form, particulars of claim and – depending upon whether the claim relates to patent infringement or revocation – either particulars of infringement or grounds of invalidity. For high-value claims before the Patents Court, the particulars are high-level at this early stage, but care should be taken to ensure that the pleadings comply with any relevant civil procedure rules and practice directions. This is also the case for the defendant’s response in its defence and any counterclaim, with detailed information following when the timetable to trial is set, particularly at the disclosure/discovery and expert evidence stages. Amendments to the pleaded case are permissible with the agreement of the opposing party or the court. The possibility of amending the case in a significant fashion becomes less likely as the case nears trial, owing to the greater potential prejudice to the opposing party.
As standing is not required to initiate revocation proceedings, such proceedings could theoretically be brought as collective actions; however, this has not happened yet.
It is an actionable offence for a patent proprietor to threaten to sue for patent infringement against a suspected or potential infringer when the threat is unjustified (Section 70A Patents Act). However, there are otherwise no restrictions on the owner of an intellectual property right asserting its rights against others. If a defendant believes they are being sued baselessly, they have an option to apply for summary judgment in the early stages of the case.
Many telecommunications patents are encumbered by declarations to the European Telecommunications Standards Institute (ETSI), which contains a contractual derogation of the automatic right to seek an injunction for patent infringement.
Only the proprietor(s) of the patent or an exclusive licensee can bring an action for patent infringement. Note that:
English law draws a distinction between acts of direct patent infringement and indirect patent infringement.
There is a distinction between the remedies available for direct and indirect infringement. The remedies for patent infringement are set out in 6.1 Remedies for the Patentee.
A different test for infringement applies to process claims under English law compared to product claims.
English Courts adopt a “purposive” approach to construing patent claims to determine the scope of the claims. In particular, the English Court will consider the words of the claim as understood by a skilled person in the context of the patent (Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 (HL)). A patent’s prosecution history will ordinarily not be considered except in exceptional circumstances.
More recently, the UK Supreme Court in Actavis UK Ltd and others v Eli Lilly ([2017] UKSC 48) have developed and applied a “doctrine of equivalents” in infringement claims by applying a three-step test to determine whether there is infringement by an “immaterial” variant.
In order to establish infringement by equivalents, a patentee would have to establish that the answer to the first two questions was “yes”, and “no” to the third.
Other than non-infringement arguments, there is a wide range of defences to an infringement claim under English law, including the following.
Statutory Defences
Other Defences
Expert evidence on patent infringement and validity issues is key in English patent litigation and can only be adduced with the court’s permission. Ordinarily, each party calls their own expert witness(es) (though the court may direct that evidence should be given by a single joint expert, which is rare).
The overriding duty of an expert witness is to assist the court on matters within their expertise, and they must remain impartial. In cases with more than one expert on each side, the court may consider that experts should have the opportunity to discuss their views with the other experts on the same side as they would have in the hypothetical skilled team. It is rare for the court to appoint an expert, but it is possible. The court may appoint scientific advisers; however, this is also rare.
The claims of a patent are construed as part of the infringement action (alongside any counterclaim for invalidity). Procedurally, once the parties to the action file their initial claims, defences and/or counterclaims, the court will make orders requiring the parties to file more detailed “Statements of Case”, which will address matters of claim construction on infringement and invalidity. The key to claim construction issues in English litigation will usually be the reports of the expert witnesses.
The English court does not usually, of its own motion, seek or receive third-party opinions in a patent infringement or invalidity action (see also 3.6 Role of Experts).
Revocation of a patent can be sought before the UK IPO or the courts. A claim for revocation can be made pre-emptively in order to clear the way and obtain freedom to operate or can be raised as a counterclaim to infringement proceedings.
A party seeking revocation of a patent will seek, by way of remedy, an order of the court for the unconditional revocation of the patent and may also seek a declaration by the court that the patent is invalid. Revocation of a patent by the court or the UK IPO has effect ab initio – ie, the patent is treated as if it had never been granted.
There are no formal standing requirements with respect to a revocation action – any person can apply to revoke a patent, regardless of intention and even in the absence of any commercial interest in the revocation of that patent.
The court or the UK IPO may revoke a patent on any of the following grounds, set out in Section 72(1) of the Patents Act 1977 and derived from Article 138 EPC.
Partial revocation is possible – ie, some of the patent claims might be found to be valid, and others might be found to be invalid.
A patent owner can apply in writing to the UK IPO to amend their patent, identifying the proposed amendment and stating the grounds on which the amendment is made; following this, the UK IPO may grant the amendment with any conditions that it sees fit. If there are pending proceedings before the court or the UK IPO, in which proceedings the validity of the patent might be put in issue, the amendment is not permitted as of right.
Conditional amendments (ie, in the event that the claims as granted would otherwise be found invalid) are permitted in England and Wales, and when making an application to amend, the patent owner must state whether or not it will contend that the original, un-amended claims are valid.
Applications to amend must be served on the other parties to the litigation as well as on the Comptroller General of Patents, Trade Marks and Designs at the UK IPO and the application must be advertised in the UK IPO’s patents journal (unless the court orders otherwise), as amendments sought by the patent owner during proceedings before the court or the UK IPO may be opposed by any person (whether or not a party to the proceedings).
If an application to amend is made to the court, the UK IPO will prepare a report for the benefit of the court as to whether it considers the amendments to be allowable. The court or the UK IPO has discretion as to whether to allow an amendment sought in revocation proceedings but must take into account relevant principles under the EPC.
Any patent amendment is effective as if it were made from the date of grant of the patent.
Post-trial amendments aimed at setting up a new claim to save a claim found invalid at trial are likely to be refused if a new trial on the validity of the proposed new claims is required.
There is no bifurcation in England and Wales. Issues of infringement and validity are dealt with in the same proceedings and at the same trial, and decisions in respect of infringement and validity are handed down as part of the same judgment.
Typical Timeline of Patent Infringement Proceedings
In intellectual property rights proceedings, patent litigation proceedings in England and Wales follow a relatively structured timeline prescribed by the Civil Procedure Rules and the Patents Court guide. The Patents Court endeavours to bring all patent cases on for trial within 12 months of the claim being issued (not including cases being expedited or streamlined by other means such as the shorter trial scheme) (see the Chancellor of the High Court’s Practice Statement dated 1 February 2022).
The typical timeline of patent litigation proceedings involves several key procedural steps outlined below.
The Trial
In patent litigation proceedings in England and Wales, there is typically only a single trial hearing to determine infringement and validity issues. However, multiple trials may occur if a claimant asserts more than one patent, necessitating separate trials for each patent.
Witnesses
Parties in patent litigation may rely on both fact and expert evidence. The case management conference determines the number of witnesses and the timeline and scope of their evidence unless agreed otherwise. The type and number of witnesses depend on the nature and complexity of the proceedings. Fact witnesses provide evidence in chief through witness statements, and experts present their evidence through expert reports signed by a statement of truth. Witnesses are called to testify at trial and undergo cross-examination by the opposing party. Unlike some jurisdictions, there is no direct examination in patent litigation proceedings in England and Wales; the written evidence serves that purpose.
Judgment and Remedies
In most patent litigation cases, particularly those involving complex issues, splitting the trials for liability and quantum is common. After the trial, the judge typically reserves judgment for a later date, which may take several months. Subsequently, the parties attend a final order hearing to determine the form of the final order and address any remaining issues, such as costs. In cases where costs cannot be agreed upon, a detailed assessment hearing is convened to determine the matter of costs.
The Decision-Makers in Patent Litigation Proceedings in England and Wales
In the context of civil proceedings in England and Wales, the determination of cases relies on the expertise of judges rather than a jury. Not all judges within the Patents Court have technical intellectual property backgrounds; however, a number of them do. Usually, cases involving more complex technical issues (in terms of the patent, the prior art, the infringement issues, and likely evidence) will be heard by a suitably qualified Patents Court Judge (Patents Court Guide, paragraph 3). Notwithstanding that, it is pertinent to note that interim hearings in complex technical patent cases might still be presided over by non-technical Patents Court Judges.
Parties involved in patent litigation proceedings do not exert influence over the selection of judges. The assignment typically depends on the availability of the court and judges, taking into consideration any existing conflicts that might impact their impartiality.
The avenues for parties to resolve proceedings are largely focused on encouraging amicable resolutions through negotiations and alternative dispute resolution (ADR) mechanisms. ADR is discussed further at 9.1 Type of Actions for Intellectual Property. Noteworthy is the court’s power to mandate parties to engage in ADR, with recent pronouncements from the Court of Appeal (in Churchill v Merthyr Tydfil County Borough Council [2023] EWCA Civ 1416) affirming the court’s ability to order parties to participate in “non-court-based dispute resolution”. This underscores the judiciary’s commitment to facilitating settlements through proactive measures.
In addition to the voluntary nature of negotiations and ADR, the legal framework in England and Wales has certain mechanisms designed to incentivise parties to reach a settlement. Notably, “Part 36” and “Calderbank” offers are tools that offer cost incentives to encourage the parties to consider settlement seriously. The Civil Procedure Rules, Part 36 procedure stands out as a beneficial mechanism (in particular for claimants), providing a structured framework that offers advantageous cost consequences. This procedure, tailored to expedite settlements, can be a useful tool in patent litigation proceedings.
The case can be settled by an order agreed between the parties and sealed by the court. Often a “Tomlin” order is used if there are confidential settlement terms.
The interplay with other court proceedings, such as parallel revocation/infringement actions and the issuance of anti-suit injunctions, can significantly impact the course of proceedings.
Parallel Revocation/Infringement Proceedings
The court may consider staying infringement proceedings pending the resolution of a parallel revocation action in another forum, including in the European Patent Office; however, it is not a requirement, and often cases are not stayed in light of parallel proceedings (eg, Neurim and Anor v Generics (UK) Ltd and Anor [2021] EWHC 2897 (Pat)).
Anti-Suit Injunctions
Whilst foreign anti-suit injunctions are not automatically binding on the courts in England and Wales, their existence may prompt a careful examination of jurisdictional issues and fairness within the ongoing proceedings in England and Wales. The courts will assess the relevance and validity of such injunctions, taking into consideration their potential impact on the current litigation in determining whether or not to enforce them.
Influence on Current Proceedings
The influence of parallel actions and anti-suit injunctions in patent litigation in England and Wales depends on the specific circumstances of each case. Courts strive to balance efficiency in dispute resolution with the principles of fairness in furtherance of the overriding objective.
The remedies that a patentee may seek and that may be granted on a finding of patent infringement (pursuant to Section 61 of the Patents Act 1977) include:
Injunction
Injunctions are discretionary in England. The factors relevant to exercising that discretion in a preliminary injunction context are addressed in 2.7 Interim Injunctions. Patents provide exclusionary rights and if a patent is shown to be valid and infringed, the court will typically grant a final injunction (the effect of which might be stayed pending any appeals). However, as injunctions are discretionary, the court will consider if an injunction is an appropriate remedy or whether, for example, a licence would be more appropriate, proportionality and other considerations, including public interest factors. A specific type of injunction unique to patent litigation relating to standards-essential patents is the “FRAND injunction”, which bites unless and until the infringer enters or undertakes to enter into a FRAND licence.
Damages or Account of Profits
A successful claimant is entitled to elect for damages or an account of profits, but not both. A court may use its discretion to award damages instead of an injunction. In taking into account damages, a successful claimant should be put in the same position as they would have been if the infringement had not occurred, provided that the claimant proves its losses are foreseeable, caused by the wrong, and not excluded from recovery by public or social policy (see Gerber v Lectra [1997] R.P.C. 443 at 452 and Lord Wilberforce in General Tire & Rubber Co v Firestone Tyre & Rubber Co Ltd [1976] R.P.C. 197 at 212). Damages are recoverable from the application’s publication date provided that the infringing act would have infringed the claims prior to publication (pursuant to Section 69 of the Patents Act 1977). Exemplary damages are available in certain circumstances (such as where the infringement is oppressive, arbitrary or unconstitutional). The court must also consider any unfair profits made by the infringer where they have infringed with knowledge (pursuant to Article 13 of the IP Enforcement Directive Regulations 2006, which has been implemented in the UK by Article 3 of the Intellectual Property (Enforcement, etc) Regulations 2006). Interest may be awarded on all sums payable from the date of each infringement complained of.
An account of profits is supposed to deprive the defendant of the profits they have made improperly by way of infringement and transfer any of that benefit to the claimant. There may be a need for the apportionment of profits if only part of a product or process is infringed upon. The quantum of damages or account of profits is decided in a separate hearing following the main infringement proceedings. Given the time and evidence involved in damages inquiries, the parties often reach a settlement prior to the quantum trial.
Order for Delivery Up or Destruction
Pursuant to Section 67(1)(b) of the Patents Act 1977, the patentee who successfully sues for infringement can obtain an order for the destruction or delivery up of infringing goods in the possession of the defendant. This usually includes goods in the UK and in the defendant’s custody, power or control on the day that the order is made. The infringing party may be ordered to confirm that it has done so and/or what steps it has taken to comply and will be ordered to disclose any infringing goods in its possession or power. An order for delivery up and destruction may be stayed pending appeal.
Relief for Infringement of Partially Valid Patent
If a patent is found to only be partially valid, a patentee may still obtain relief in respect of the valid parts of the patent, including damages and an account of profits (pursuant to Section 63(1) of the Patents Act 1977).
Certificate of Contested Validity
The patentee is entitled to a certificate of contested validity where they have successfully defeated a claim of invalidity. At the court’s discretion, this can carry cost implications for future challenges to the patent.
Costs
The successful party may also be entitled to recover their costs (or a proportion of their costs) from when the action is filed (including court fees). Costs are discussed further in 8.3 Responsibility for Paying the Costs of Litigation.
A successful defendant has the same rights as a prevailing claimant, as applicable. For instance, if the defendant is a patentee and the claimant fails to show invalidity/non-infringement, the defendant would have each of the remedies set out in 6.1 Remedies for the Patentee. Further relief that can be sought includes declarations of non-infringement and Arrow-style declarations (as referred to in 2.2 Third-Party Remedies to Remove the Effects of Intellectual Property).
If the defendant is not the patentee, a successful defendant in an infringement action would also be entitled to recover their costs (as referred to in 6.1 Remedies for the Patentee), either proportionate and reasonable or on an indemnity basis. Similarly, as discussed in 6.1 Remedies for the Patentee, if a defendant is successful in partly invalidating the patent, the defendant only has to pay damages or an account of profits with respect to the parts of the patent found to be valid.
If the defendant has been subject to an interim injunction, they may be entitled to claim damages on any cross-undertaking after an interim injunction is discharged. The court will assess the damages “upon the same basis as that upon which damages for breach of contract would be assessed if the undertaking had been a contract between the plaintiff and the defendant that the plaintiff would not prevent the defendant from doing that which he was restrained from doing by the terms of the injunction” (see Smith v Day (1882) 21 Ch D. 421 per Brett LJ at p. 427).
If the defendant or its customers has been the subject of threats, there also exist remedies for groundless threats of infringement proceedings, whereby the alleged infringer can seek damages, an injunction to prevent further threats, and a declaration that the threat lacked justification.
The types of remedies available in patent litigation have been set out in 6.1 Remedies for the Patentee and 6.2 Rights of Prevailing Defendants.
The court has discretion as to whether or not to stay an injunction pending appeal, and it applies the balance of convenience test in exercising its discretion. For example, in the case of public inconvenience, the immediate operation of an injunction may be suspended to minimise such inconvenience or to avoid extensive unemployment.
Where a stay is granted for an injunction pending appeal, it is generally ordered that it be stayed for such time to enable the defendants to give notice of appeal and to continue in force until the appeal has been pursued with due diligence. The appellant, subject to the stayed injunction, must keep a record of their accounts relating to the disputed product/process or otherwise make payments into escrow. The patentee is often given the option of whether to enforce the injunction pending appeal (subject to an appropriate cross-undertaking in damages). The court has taken the following considerations into account when deciding whether to exercise its discretion to grant a stay.
Whether the party requesting the stay is willing to provide financial relief (Adaptive Spectrum and Signal Alignment Inc v British Telecommunications Plc [2014] EWCA Civ 1513).
Timeline for Appeals
In patent proceedings, appeals to the Court of Appeal typically must be filed within a timeframe of 21 days after the judgment is handed down. It is customary in patent proceedings for this period to be stayed pending the issuance of the final order from the first instance proceedings. This ensures that the clock for the 21-day filing period starts running from the date of the final order, allowing parties a reasonable window for lodging appeals. This is a common approach in patent proceedings and recognises the need for clarity on the final judgment before initiating the appellate process.
Rules and Alternative Procedure
Whilst patent appeals to the Court of Appeal generally follow the same rules as other appeals to the Court of Appeal, a specific provision outlined in Annex G of the Patents Court Guide requires the parties to provide time estimates and a timetable for the appeal.
Appeals to the Court of Appeal in patent proceedings are intentionally confined to questions of law. Unlike the trial stage, where facts are thoroughly examined and determined, the appellate review does not embark on a comprehensive reassessment of the factual landscape. Instead, the focus is directed towards legal issues, ensuring that the appeal is centred on interpreting and applying legal principles relevant to the case at hand.
The appellate process does not allow a full review of the facts of the case. The Court of Appeal is not a forum for re-evaluating the evidence or reconsidering factual determinations made at the trial level. This characteristic underscores the finality and conclusiveness of factual findings reached during the trial, promoting judicial efficiency and a focused appellate review that aligns with the overriding objective. Further, the introduction of new evidence on appeal is prohibited unless it was not available at the time of the trial.
There are costs involved in first obtaining advice from a law firm as to the prospects of success of the claim, the drafting and sending of any “cease-and-desist” letters, advice on jurisdiction and service, and the preparation and service of the documents required for the commencement of proceedings (being a claim form, particulars of claim, and either particulars of infringement or grounds of invalidity). The costs of the advice and pre-litigation correspondence will differ from law firm to law firm, but the actual filing of the pleadings is a fixed cost set by the court (as referred to in 8.2 Calculation of Court Fees).
In the High Court, the claimant is required to pay a court fee to start proceedings, which is based on the value of the claim. If the claim is one for money (for example, a claim for damages or an account of profits), the fee payable upon issue of proceedings is 5% of the amount for claims worth between GBP10,000–GBP200,000, or GBP10,000 for claims worth more than GBP200,000. If the claim is non-monetary (such as for injunctive relief), then the fee is GBP626. If the claimant seeks monetary and non-monetary relief, then both fees must be paid. The court fees are not dependent on how many patents or defendants there are.
Whilst the claimant is required to pay the court and trial fees, each party is responsible for paying its own attorney fees and expenses during the proceedings until there is a final decision.
Generally, costs follow the event, and the losing party is required to reimburse the prevailing party for the litigation costs. These costs include court fees, expenses and attorney fees. The court has a general discretion under Part 44 of the Civil Procedure Rules as to the amount of costs to be ordered, the manner in which they are paid and when they are to be paid. As stated in 6.1 Remedies for the Patentee, the court will take into account any more discrete issues on which the parties have been successful or unsuccessful, settlement offers from either party, the conduct of the parties throughout the litigation, and the reasonableness of the costs of either party.
The successful party may recover proportionate and reasonable costs (which equate to around 60%–70% of their costs) if they win on all issues raised in the litigation or on an “indemnity basis” if the losing party has conducted itself unreasonably (which equates to around 70%-80% of their costs). In any award of indemnity costs, the court will take into account factors such as any discrete issues that the ultimate winner may have lost on, as well as any settlement offers from either party. The court will also consider either party’s conduct throughout the litigation and can address unreasonable or improper conduct in its award of costs.
On 1 January 2024, a GBP500,000 cost cap on liability and GBP250,000 on quantum was introduced to patent cases dealt with under the shorter trials scheme procedure of the High Court, which is a streamlined procedure for patent litigation intended for smaller-scale patent disputes.
There is a cap of GBP60,000 on recoverable costs for a final determination on liability and GBP30,000 on quantum in the IPEC, a specialist list of the Chancery Division of the High Court. It was established to deal with claims of less value, which are shorter and less complex.
As mentioned in 5.3 Settling the Case, the Courts of England and Wales encourage and may require parties to disputes of any kind, including intellectual property disputes, to actively engage in ADR procedures. This is a requirement in the Civil Procedure Rules, and parties may be expected to raise the option of ADR even before the commencement of traditional legal proceedings in the courts.
Although the most common option to resolve large-scale patent disputes is through the courts, certain forms of ADR are still utilised. The most common forms of ADR used in patent disputes include arbitration and mediation. The need to arbitrate disputes is often written into patent licences, whereby related disputes should be settled through the procedure of an agreed and accredited arbitration forum.
An assignment of a UK patent or patent application must be in writing and signed by the assignor – in practice, it is usual for both parties to sign the assignment.
No approval of the UK IPO is required to effect an assignment of a patent or a patent application.
There is no requirement to register an assignment at the UK IPO. However, it is recommended to do so, as failing to register an assignment can have significant consequences.
A UK patent or patent application can be assigned by contract, and the assignment may or may not be registered at the UK IPO (see 10.1 Requirements or Restrictions for Assignment of Intellectual Property Rights). Registration of an assignment requires completion of Patents Form 21, with the completed form to be sent to the UK IPO. Patents Form 21 can be used for more than one patent or patent application, provided that each relates to the same assignment transaction.
If only the assignor signs the form, the UK IPO will usually consider the form to be sufficient evidence to proceed to register the assignment and will not usually require any additional evidence. If the assignor does not sign the form, documentary evidence of the assignment (for example, a copy of the assignment document) must be filed with the form. There is a GBP50 fee for filing the form.
There is no formal requirement for a licence to be valid in writing, but it is advisable to do so in order to ensure clarity regarding the terms of the licence.
As with assignments, there is no requirement to register a licence at the UK IPO. However, it is recommended to do so, as failing to register a licence can have significant consequences.
The process for registering a licence of a UK patent or patent application is the same as registering an assignment of a UK patent or patent application as described in 10.2 Procedure for Assigning an Intellectual Property Right.
30 St Mary Axe
London EC3A 8AF
United Kingdom
+44 (0)20 7469 2150
+44 (0)20 7469 2001
nicola.dagg@kirkland.com www.kirkland.com2024 UK Patent Litigation
The UK patent litigation market has remained active in 2024. A variety of patent cases have been heard, and judgments have been delivered in a typically broad range of sectors, including the SEP/FRAND, life sciences, pharma, and medical device sectors. These cases have resulted in a range of important legal and practice-related trends and developments. 2024 has also been a year of adjustment at the UPC as its procedural and substantive jurisprudence continues to develop.
A substantial pipeline of patent trials is set to keep the Court and legal community occupied throughout 2025 and beyond. The English Courts continue to innovate, positioning the UK as a key jurisdiction in the global and European markets. In fact, most of the decisions discussed in this article were part of multi-jurisdictional disputes where UK litigation played a critical role in the overall strategy. By providing accessible, transparent, and well-reasoned decisions on complex and technical intellectual property issues and by demonstrating a willingness to understand and engage with the intricate economics underlying many of these cases, the English Courts will maintain the UK's status as a leading jurisdiction. This will enable them to play a significant and strategic role in multinational disputes. Below, you will find some notable themes and developments in the case law.
SEP/FRAND Litigation
Following the second and third-ever global FRAND rate-setting decisions in the UK last year in InterDigital v Lenovo and Optis v Apple, 2024 has proven to be another bumper year for SEP/FRAND litigation in the UK. This year, emboldened by these rate-setting decisions and with full confidence in the pedigree of UK Courts, it has largely been the implementers leading the charge. UK Courts have demonstrated a willingness to devise novel case management mechanisms such as interim licences to preserve the integrity of the FRAND process (Panasonic v Xiaomi) and accept jurisdiction in novel cases (Lenovo v InterDigital). In doing so, they have solidified their status as world leaders in case-managing FRAND litigation and reaffirmed their unique role in resolving global FRAND disputes.
At the same time, this year, several major UK FRAND cases were settled. This includes Nokia and OPPO, who signed a global cross-licence agreement after litigating before the UK Courts for 3 years. Likewise, Panasonic, Xiaomi and OPPO put an end to their UK proceedings, but only after the Court of Appeal issued a groundbreaking decision granting Xiaomi the first ever “interim” FRAND licence in Panasonic v Xiaomi [2024] EWCA Civ 1143. And then, shortly before a rate-setting judgment was expected, InterDigital and OPPO also agreed to settle their dispute.
2025 promises to be another busy year for SEP/FRAND litigation, with FRAND trials scheduled for cases including Lenovo v Ericsson and Alcatel/Nokia v Amazon and other cases such as MediaTek v Huawei and Lenovo v ZTE pending. A new frontier has also emerged in the form of patent licensing "pools" – the Court of Appeal’s jurisdiction decision on this in Tesla v InterDigital & Avanci, expected in early 2025, is eagerly anticipated.
Another Court of Appeal FRAND rate-setting decision – InterDigital v Lenovo
In a key decision on 12 July 2024 (InterDigital v Lenovo [2024] EWCA Civ 743), the Court of Appeal largely upheld a first-instance decision granting a FRAND licence.
The Court of Appeal (Arnold, Nugee & Birss LJJ) slightly increased the per-unit FRAND rate to InterDigital's portfolio of cellular patents from (USD) 17.5 cents to 22.5 cents, which was still significantly lower than the 49 cents rate effectively sought by InterDigital at first instance. The Court broadly accepted the first instance Judge’s reasoning, agreeing that comparable licences were “the best guide”, but found that he had failed to take into account non-FRAND factors when considering comparable licences. In arriving at the 30 cents per-unit rate, Arnold LJ stressed that the Court’s task in setting a FRAND rate “is not a task that admits of the kind of mathematical precision which the Judge applied”.
The Court's first-instance finding also confirmed that UK statutory limitation periods do not apply to exclude liability for past sales. Interest was also awarded with respect to the liability incurred for past sales.
Interim licences – Panasonic v Xiaomi
In 2024, the English Courts have been grappling with curly issues arising where an implementer has given an unconditional undertaking to be bound by the FRAND terms to be determined by an English Court, but the patentee is nonetheless seeking and/or obtaining injunctive or similar relief in parallel foreign proceedings. One mechanism sanctioned by the Court of Appeal in Panasonic v Xiaomi to address this situation is an interim licence, which, if entered by the parties, would govern the period during which the UK FRAND rate-setting process is underway. This is a developing area of jurisprudence, and the extent to which the English courts will act to preserve the integrity of the UK FRAND rate-setting process by awarding interim licences or other mechanisms remains to be seen. In another case (Lenovo v Ericsson), the first instance Judge recently rejected an application for an interim licence, but the decision is on appeal.
In Panasonic v Xiaomi, the saga took a decisive and final turn in the UK after the Court of Appeal overturned the first instance judgment and ruled in favour of Xiaomi, granting them the first-ever interim FRAND licence. Xiaomi filed applications for a FRAND-first trial listing and expedition and successfully obtained an expedited pure-FRAND first trial. Xiaomi also elicited an unconditional undertaking from Panasonic to be bound by the UK FRAND determination. This is of particular importance in a context where the UK action was commenced alongside a series of actions in the UPC, Germany, and China. Panasonic was initially prepared to give another undertaking not to enforce any injunctions obtained in parallel proceedings in Germany or the UPC but changed its position shortly after. In these circumstances, the Court noted that Panasonic's clear intention to seek an injunction from the German courts or the UPC in order to reach a negotiated settlement with Xiaomi - rather than waiting for the FRAND rate to be established in the UK - was not in line with its commitment to FRAND principles. In any case, Xiaomi had offered to take an interim licence to Panasonic's portfolio pending the English Court’s FRAND determination so that Panasonic would not incur any loss. Based on these facts, the Court decided that Panasonic was not acting in good faith as required by Clause 6.1 of the ETSI policy, which paved the way for a declaration of an interim licence. Shortly after that Judgement, the parties announced that they had settled their case, and the FRAND trial due to start in October 2024 was subsequently vacated.
AI-based inventions – Comptroller-General v Emotional Perception AI
The Court of Appeal recently addressed the issue of the patentability of artificial neural networks (ANNs). ANNs are structured with layers of interconnected neurons, resembling the organisation of neurons in the human brain. They take a set of input information and use weights and biases as parameters to produce output information. ANNs are the backbone of many machine learning and generative AI systems used in contemporary society.
The claimed invention consisted of an ANN configured to recommend media files (eg, music recommendations) based on human perception and emotion, irrespective of the genre of music and other people's tastes.
On appeal, the Judges had to decide two questions:
The Comptroller had previously answered yes to both questions, and the first-instance Judge had decided no on the first question (and, in the alternative, no on the second question).
The Court of Appeal overturned the first instance decision, answering yes to both questions. As to the first question, Birss LJ (Arnold & Nicola Davies LJJ agreeing) held that an ANN was “clearly a computer" – that is, a machine for processing information – and further that the weights and biases, which the ANN uses to produce output, function as a program. As to the second question, Birss LJ held that other than the step of sending the recommended file to a user, the whole contribution consisted solely of a computer program.
The Court of Appeal also observed, in obiter, that even if the claim was not an unpatentable computer program, it might well have been excluded from patentability as an unpatentable mathematical method.
Given continued investment and innovation in the development of machine learning and generative AI models, the decision may have broad implications. However, the decision does not spell the death of patents for computer-implemented inventions involving ANNs – the Court stressed that “[v]ery many computer-implemented inventions are outside the exclusion and are patentable as a result”, providing two examples of patented inventions which “would have been just as patentable if the computer involved had been or used an ANN”.
In December 2024, the UK Supreme Court granted Emotional Perception permission to appeal. The Supreme Court’s decision will provide important guidance on the patentability of ANN-based inventions and the scope of the computer program exception under the Patents Act 1977.
Life Sciences, Pharma and Medical Devices
2024 has been another busy year for life sciences and medical device patent litigation in the UK, with a number of decisions relating to blockbuster medicines and medical devices being handed down. This year marked the conclusion (subject to an ongoing appeal) of the highly publicised spat between Moderna and Pfizer/BioNTech. The initial ruling resulted in a mixed outcome for both companies: Pfizer has been granted permission to appeal, while the High Court denied Moderna's request.
Consistently with trends in previous years, most of these cases resulted in the invalidation of the patents at issue (eg, Sandoz v Biogen; Pfizer v GSK; Samsung Bioepis v Janssen; BioNTech/Pfizer v CureVac; Abbott v DexCom; Sandoz v Bayer; Advanced Cell Diagnostics v Molecular Instruments). However, there have also been several recent decisions which have bucked this trend in whole or in part (Moderna v Pfizer/BioNTech; Accord/Sandoz/Teva v Astellas; Pfizer v UniQure). These recent wins for patentees show that the English Courts are willing to uphold the validity of patents in appropriate cases.
Unlike in previous years, the patent cases this year primarily involved the application of established legal principles to factual scenarios. However, there have been a number of interesting practice-related developments, including:
Patent decisions on cutting-edge life sciences technology
2024 has seen the English Courts grapple with patents relating to inventions in a number of cutting-edge areas within the life sciences sector.
In the second half of the year, we saw the first two UK patent decisions regarding COVID-19 mRNA technology in Moderna v Pfizer/BioNTech and BioNTech/Pfizer v CureVac. In Moderna v Pfizer/BioNTech ([2024] EWHC 1695 (Pat)), the High Court (Meade J) upheld the validity of one of Moderna's patents relating to modified mRNA but struck down another patent claiming betacoronavirus mRNA vaccines comprising a spike protein in a lipid formulation for obviousness. In a separate trial ([2024] EWHC 1648 (Pat)), the High Court (Richards J) found that Moderna’s 2020 pledge not to enforce its COVID-19 patents gave Pfizer/BioNTech non-contractual consent to perform acts of patent infringement until the date Moderna withdrew its pledge. In BioNTech/Pfizer v CureVac [2024] EWHC 2538 (Pat), the High Court (Meade J) found two of CureVac's patents relating to a split poly(a) tail in mRNA were invalid. Curevac acknowledged the invalidity of a third patent but plans to argue on appeal to the UK Supreme Court that the Supreme Court’s decision regarding insufficiency in the Warner-Lambert v Generics case was incorrect.
In October 2024, we also saw one of the first English patent decisions relating to gene therapy in Pfizer v uniQure [2024] EWHC 2672 (Pat). The High Court (Hacon J) held that the claimed invention was not obvious in light of a published patent application as there was no reasonable expectation of success, relying heavily on secondary evidence of inventiveness and finding that the prior art disclosure relied upon by Pfizer would have been viewed by the skilled team “as a scientifically meaningless bit of patent drafting”.
Unlike in the EPO and other jurisdictions such as Australia, CRISPR patent litigation has yet to make its way to the UK. This is another exciting field within the life sciences sector, and it may see activity over the coming years.
Biotech patent litigation continues to grow, but small molecule patent litigation remains active
This year has been another big year for biotech patent litigation in the UK, which continues to grow in popularity as more and more biotechnology-related patent portfolios reach their expiry date. There has been impressive breadth in subject matter, spanning biosimilars (eg, Sandoz v Biogen; Samsung Bioepis v Janssen; Amgen v Alexion; Formycon v Regeneron), rival biological vaccines (Moderna v Pfizer/BioNTech), DNA diagnostic methods (Advanced Cell Diagnostics v Molecular Instruments) as well as biotechnology-related entitlement disputes (Hill v Touchlight; Bionome Technology v Clearwater) among other areas.
However, traditional small molecule patent litigation remains active, with important decisions on blockbuster medicines such as rivaroxaban (Sandoz v Bayer) and enzalutamide (Accord/Sandoz/Teva v Astellas). In Accord/Sandoz/Teva v Astellas [2024] EWHC 2524 (Pat), the High Court (Mellor J) held that a claim to the compound enzalutamide, used to treat prostate cancer, was not obvious in light of prior art disclosing a structurally similar compound to enzalutamide. Mellor J held that the generics' primary argument was tainted by hindsight and was not satisfied that their secondary argument had been trailed in evidence.
Medical devices litigation continues apace
Likewise, patents relating to medical devices continue to be litigated in the UK in 2024. The longstanding battle between Abbott and DexCom concerning continuous glucose monitoring devices, also active in the UPC, continues to rage on, with the High Court invalidating four of Abbott’s patents in January and in June finding that one of DexCom's devices did not infringe the asserted patent, which in any event was invalid for obviousness. Several other cases between Abbott and DexCom are ongoing. There are also ongoing cases between Insulet and Menarini/EOFlow (insulin pumps) and Meril and Edwards (heart valves), whilst Abbott settled its UK dispute with SiBio this year in relation to its devices.
Supplementary Protection Certificates (“SPC”)
The UK also continues to develop its jurisprudence in relation to supplementary protection certificates (“SPC”), with the Court of Appeal finding that a claim to an active ingredient A in combination with active ingredients B and C cannot be the subject of an SPC based on a marketing authorisation for A alone (Newron), and the High Court finding that a claim to an excipient which enhances the effect of an active ingredient falls outside the scope of SPC protection (Halozyme).
UPC Developments
Only a year and a half following its opening, the UPC has been busy dealing with a variety of issues in a wide range of sectors, making it an important forum for handling patent disputes in Europe. According to the UPC's most recent caseload report, the German UPC local divisions have proven to be the forum of choice for patentees, with 71% of the caseload as of 30 November 2024.
In 2024, many parties were keen to see how the UPC’s approach to preliminary injunctions (“PI”) would develop following the decision to grant a PI in 10x Genomics v NanoString in 2023. The UPC's approach in 2024 has proven to be more balanced than expected. In 10x Genomics v NanoString, the UPC Court of Appeal overturned the Munich Local Division’s decision on the basis that the patent's invalidity was "predominantly probable", thus giving due deference to validity/invalidity issues. The Court also set out a higher standard to assess whether the requirement of infringement with “a sufficient degree of certainty” was met. The UPC has additionally emphasised that patentees seeking PIs need to act urgently, rejecting a PI application in Ericsson v Asustek for lack of urgency.
The UPC's approach to obviousness has also developed in 2024. In Sanofi v Amgen, the Munich Central Division held that the first step of the obviousness approach consisted of determining a “realistic starting point" for the skilled person, which appears to provide more flexibility than the EPO's standard problem-solution approach of identifying the closest piece of prior art. This shows that the UPC is willing to build a body of specialised jurisprudence of its own making instead of unthinkingly relying on existing national law or EPO decisions. Future decisions will show if other divisions will be willing to build a caselaw consistent with this approach.
Finally, the UPC recently dealt with its first two FRAND cases in Panasonic v OPPO and Huawei v Netgear. The Mannheim and Munich Local Divisions, respectively, found OPPO and Netgear to be infringing. Adopting a "German-style" approach, they refused OPPO's and NetGear’s FRAND defence on the basis that they did not behave in a FRAND-like manner.
Kirkland & Ellis International LLP
30 St Mary Axe
London EC3A 8AF
United Kingdom
+44 (0)20 7469 2150
+44 (0)20 7469 2001
nicola.dagg@kirkland.com www.kirkland.com